GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scilex Holding Co (NAS:SCLX) » Definitions » Total Current Liabilities

Scilex Holding Co (Scilex Holding Co) Total Current Liabilities : $252.73 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Scilex Holding Co Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Scilex Holding Co's total current liabilities for the quarter that ended in Mar. 2024 was $252.73

Scilex Holding Co Total Current Liabilities Historical Data

The historical data trend for Scilex Holding Co's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scilex Holding Co Total Current Liabilities Chart

Scilex Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
- 78.48 169.42 44.84 250.38

Scilex Holding Co Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.60 103.58 228.58 250.38 252.73

Scilex Holding Co Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Scilex Holding Co's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=140.701+109.188
+Other Current Liabilities+Current Deferred Liabilities
=-2.8421709430404E-14+0.491
=250.38

Scilex Holding Co's Total Current Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=158.598+93.654
+Other Current Liabilities+Current Deferred Liabilities
=0+0.48
=252.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Scilex Holding Co Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Scilex Holding Co's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Scilex Holding Co (Scilex Holding Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scilex Holding Co (NAS:SCLX) » Definitions » Total Current Liabilities
Comparable Companies
AMRN MIRA LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD LSE:GSK TSE:4568 TSE:4519 XTER:BAYN SHSE:600276 BIIB
Traded in Other Exchanges
N/A
Address
960 San Antonio Road, Palo Alto, CA, USA, 94303
Website
https://www.scilexholding.com
Scilex Holding Co is engaged in the development and commercialization of non-opioid pain management products. The company's lead product ZTlido.
Executives
Sclx Stock Acquisition Jv Llc 10 percent owner 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Jay Chun director C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Stephen Hoi Ma officer: Chief Financial Officer C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Tien-li Lee director C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sorrento Therapeutics, Inc. 10 percent owner 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
David Lemus director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Dorman Followwill director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Henry Ji director, officer: Executive Chairperson 5370 RUETTE DE MER, SAN DIEGO CA 92130
Jaisim Shah director, officer: See Remarks C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Elizabeth Czerepak officer: See Remarks 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Suneel G Kaji director 25/28 OLD BURLINGTON STREET, LONDON X0 W1S 3AN
Steve Myint director C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632

Scilex Holding Co (Scilex Holding Co) Headlines

From GuruFocus

Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Avai

By Marketwired • 09-11-2023

Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido�, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to S

By Marketwired • 09-14-2023

Thinking about buying stock in Nio Inc, VinFast Auto, Mira Pharmaceuticals, Tivic Health Systems, or Scilex Holding?

By PRNewswire • 08-30-2023

Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder

By Marketwired • 09-13-2023

Scilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock Price

By Marketwired • 10-08-2023

Sorrento Announces Launch of Voluntary Offering to Dividend Short Holders with Deadline to Participate by July 27, 2023

By PRNewswire • 07-21-2023

/C O R R E C T I O N -- Sorrento Therapeutics, Inc./

By PRNewswire • 07-21-2023

Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.

By Marketwired • 09-21-2023

Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido�, for the Treatment of Acute Low Back Pain

By sperokesalga sperokesalga • 05-04-2023

Thinking about buying stock in Alibaba Group, Uber, Walt Disney Co, ChargePoint Holdings, or Scilex Holding?

By PRNewswire • 11-17-2023